Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02131220

Acronym

ERUPTION

Enrollment

362

Registered

2014-05-06

Start date

2015-11-30

Completion date

2017-09-30

Last updated

2018-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy

Keywords

No-Reflow Phenomenon

Brief summary

The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.

Interventions

DRUGnormal saline

intracoronary bolus infusion using selective catheter during PCI

DRUGProurokinase

20mg intracoronary bolus infusion using selective catheter during PCI

DRUGTirofiban

10ug/kg intracoronary bolus infusion using selective catheter during PCI

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* ST-segment elevation AMI within 12 hours of symptom onset

Exclusion criteria

* Contraindications to thrombolysis or PCI * Patients administered a fibrinolytic agent before PCI * Patients enrolled in clinical trials

Design outcomes

Primary

Measure	Time frame
Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)	At the end of Percutaneous Coronary Intervention procedure

Secondary

Measure	Time frame
ST segment resolution in ECG	3 hours post PCI procedure
peak troponin T level	in the 7 days post PCI procedure
infarction area confirmed by SPECT	30 days post PCI
incidence of major adverse cardiac events (MACE) defined as the composite of death, myocardial infarction and target vessel revascularization	30 days post PCI
plasma N terminal-proBNP levels	1 and 30 days post PCI procedure

Other

Measure	Time frame
TIMI defined total major bleeding	30 days post PCI

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026